CA-DEGREED
Degreed , the global innovator in professional lifelong learning chosen by more than one in three Fortune 50 companies, today announced the acquisition of talent academy platform, Learn In , and the return of Co-founder David Blake as CEO. Blake was previously the Co-founder and CEO of Learn In.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005917/en/
Learn In helps companies establish internal talent academies that bring together all the resources needed for building a highly skilled workforce, including the longer journey of developing deep skills. Learn In’s core features supplement those of the category-defining Degreed LXP (Learning Experience Platform), including a prepaid learning stipend card, a world-class skills marketplace and custom program builder, a tuition benefits manager, and dedicated coaching.
“A corporate capability academy goes beyond ‘a library of content,’” said global industry analyst and CEO of the Josh Bersin Company, Josh Bersin . “It’s a place people go to advance their job-related capabilities. It goes beyond technical and functional skills and focuses on the real business capabilities a company needs to thrive.”
Degreed plus Learn In will unify the broader range of development options people use, spanning daily learning to long-term upskilling for individual career growth and innovation within organizations.
Blake’s plans for the future of Degreed were divergent with the current direction, so an amicable decision was made that he return to the company as CEO and execute that vision.
Degreed thanks Dan Levin for the progress he has driven and his stewardship of the Degreed mission over the past 15 months, and is grateful for his accomplishments, including increasing our client base, establishing operational rigor for scale, and significantly expanding our partner ecosystem and overall global footprint.
“Businesses that can quickly build effective talent are the ones that will be able to deliver on strategic business goals,” said David Blake, Co-founder and CEO of Degreed . “Just as Degreed created the LXP market, Learn In has begun for talent academies. Now together, we have the product and technology to help our customers deliver business capabilities at scale with continued innovation in the learning and skills space.”
“At BMO, our strategy is to build a digitally-enabled bank that’s ready for the future. This means we need to equip employees with the skills they need for their job, their career, for the future of work, and as they follow their personal passions,” says Gina Jeneroux, Chief Learning Officer at BMO Financial Group . “As Degreed and Learn In come together, it will offer a more integrated opportunity for organizations like ours to engage employees and build a broader range of skills—from curious, ‘in-the-moment’ learning through to deeper reskilling and credentials.”
This is the fourth acquisition for Degreed, and Blake re-joins a seasoned Degreed leadership team from Bank of America, Mastercard, Danone, LinkedIn, Adobe, SAP and Saba.
About Degreed
Degreed empowers innovation through learning. As a changemaker on a global scale, we work with one in three Fortune 50 companies to spark a culture of learning across their enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need – through individual, collaborative and experiential modes of learning – to drive individual and business results. Founded in 2012, Degreed is headquartered in Pleasanton, California, with users spanning 191 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
About Learn In
Learn In helps companies establish talent academies that steer all the resources needed for building a highly skilled workforce. HR, Talent and L&D leaders use Learn In to modernize access to learning budgets and world-class programs, and to simplify the delivery of custom programs to employee groups. Learn In’s core features include a tuition benefits manager, a prepaid learning stipend card, a world-class program marketplace and custom program builder, and dedicated coaching. Now every employee can build deeper skills precisely aligned to company needs. Co-founded by the founders of Degreed, Learn In is backed by leading edtech & future-of-work investors, including Firework Ventures, Kickstart Fund, Album, GSV, and Village Global, and has been covered in CNBC, USA Today, EdTechReview, EdSurge, Fast Company, and Techcrunch.
Learn more about Learn In: Website | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005917/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom